NEOPLASMS

This early-phase study tests a new treatment called ACIT-1, which uses immune cells from a healthy donor to help fight cancer. The main goal is to find the safest dose and see if it can boost the body's immune response against tumors. The trial includes 34 adults with pancreatic …

This early-stage study tests a new drug called remzistotug in 152 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to check the drug's safety and how the body processes it, both alone and with other cancer drugs. Participants must…

This program offers taletrectinib to adults with advanced or spreading ROS1-positive non-small cell lung cancer who cannot use approved treatments or join ongoing studies. Participants must have a ROS1 gene fusion and adequate organ function. The goal is to provide potential bene…

This early-phase study tests a new experimental drug called GSK6097608, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 107 adults will take pa…

This study offers continued access to the cancer drug atezolizumab for people who were already benefiting from it in a previous Roche-sponsored trial. It includes 49 participants who need ongoing treatment and do not have local access to the drug. The main goal is to provide unin…

This study tests an experimental drug called JNJ-63723283, which helps the immune system fight cancer. It is for people with advanced cancers like lung, melanoma, bladder, and others. The goal is to find the best dose and see if the drug can shrink tumors. About 413 participants …

This early-phase study tests a new treatment for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has not responded to standard therapy or has returned. The treatment uses a patient's own immune cells (T cells) that are genetically modified to recognize and attack c…

This study offers ongoing treatment with alectinib or crizotinib to people with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. About 200 participants will continue their medication while doctors monitor for side effects and saf…

This study looks at how well the drug osimertinib combined with chemotherapy works as the first treatment for people with advanced EGFR-mutated non-small cell lung cancer. About 532 adults with stage IIIB, IIIC, or IV lung cancer that cannot be surgically removed are being observ…

This phase 2 trial tests a treatment called Lete-Cel for people with advanced synovial sarcoma or myxoid/round cell liposarcoma that has not responded to prior therapy. Lete-Cel uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer…

This study tests a special type of immune cell, called an engineered T-cell, designed to find and attack cancer cells in people with advanced solid tumors. About 103 participants with specific genetic markers (HLA-A2 and NY-ESO-1 positive) will receive these cells alone or with o…

This study is the first to test TSR-022, an experimental antibody that targets a protein called TIM-3 on immune cells, in people with advanced solid tumors. The trial has two parts: first, finding the safest dose, and second, seeing how well the drug works when given alone or wit…

This study tests if the drug bevacizumab can help adults with a rare condition called recurrent respiratory papillomatosis (RRP), which causes wart-like growths in the airways that often need repeated surgeries. About 21 participants will receive the drug through an IV after surg…

This study gives people with myelofibrosis, a rare bone marrow cancer, continued access to the experimental drug momelotinib. It aims to check the drug's long-term safety and see how it affects survival. Participants are already taking momelotinib in earlier studies and have not …

This early-phase study tests a new oral drug (GSK4524101) alone and with another drug (niraparib) in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and to see if the combination shrinks tumors. About 42…

This study is testing an experimental drug called dostarlimab (TSR-042) in people with advanced solid tumors who have run out of standard treatment options. The drug works by helping the immune system attack cancer cells. The study has two parts: first, finding the safest dose, a…

This study tests a treatment called Lete-Cel for people with advanced synovial sarcoma or myxoid/round cell liposarcoma that has not been treated before. Lete-Cel uses a patient's own immune cells that are modified in a lab to better recognize and attack cancer cells. The main go…

This study tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 785 participants will receive either dostarlimab plus chemo or a placebo plus che…

This study tests a combination of four drugs (irinotecan, dabrafenib, trametinib, and either cetuximab or panitumumab) as a second treatment option for people with advanced colorectal cancer that has a specific BRAF mutation and cannot be removed by surgery. The goal is to see if…

This early-phase study tests a new experimental drug, BI 765179, in adults with advanced solid tumors or head and neck cancer that has not responded to standard treatments. The first part finds the safest dose when given alone or with another drug (ezabenlimab). The second part t…

This study was designed for children with a type of aggressive brain cancer (high-grade glioma) that has come back after initial treatment. It planned to test an experimental virus therapy, G207, injected directly into the tumor, along with a single dose of radiation. The goal wa…

This early-phase study tests a new experimental drug called GSK3745417, given alone or with another drug (dostarlimab), in about 97 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effec…

This study tests a new drug, E7386, combined with other anticancer drugs for people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find the safest and most effective dose. About 301 participants will be involved, and the study foc…

This early-stage study tests if amivantamab, a drug that targets certain cancer cells, can be given as a shot under the skin instead of through an IV. It includes 158 adults with advanced solid tumors like lung or head and neck cancer. The main goals are to check safety, find the…

This study is testing a new cell therapy for people with Hodgkin's or Non-Hodgkin's lymphoma that has come back or hasn't responded to other treatments. Doctors take a patient's own immune cells, modify them in a lab to better target cancer, and then infuse them back. The main go…

This is a first-in-human study to test the safety and find the right dose of an experimental pill called ATV-1601. It is for adults with advanced solid tumors, including certain breast, gynecologic, and prostate cancers, that have a specific genetic change called an AKT1 E17K mut…

This study looks at whether a special type of mammogram using a contrast dye can find breast cancer more accurately than standard mammograms in women who have already had breast cancer. About 1,647 women will get both types of imaging to compare how many cancers are found and how…

This study tests whether a culturally adapted strength training program, done together with a caregiver, is feasible and beneficial for Hispanic prostate cancer survivors and their caregivers. The program involves remote group exercise classes over 3 months, with a 3-month follow…

This study tests a 7-week group program led by trained peers (not doctors) to help cancer survivors reduce anxiety and depression after finishing curative treatment. 234 adults in Denmark who completed cancer treatment within the past year and have mild-to-moderate symptoms are t…

This study looks back at medical records of 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of all side effects caused by the drug. By understanding these side effects, doctors hope to prevent or reduce them in future cancer…

This study tests a new technology that automatically adjusts the radiation beam to follow a lung tumor as it moves with breathing. Twenty adults with early-stage lung cancer or limited lung metastases will receive standard radiotherapy with this tracking system. The main goal is …

This study looks at whether educating doctors in smaller city and county hospitals can improve how they test and treat patients with advanced non-small cell lung cancer. About 1000 patients will be observed to see if more patients get the right molecular tests and targeted therap…

This study tests whether a modified clinical program can improve how doctors assess and prevent blood clots (venous thromboembolism) in cancer patients starting treatment. About 25 clinicians and their patients will take part. The program includes education for doctors and a stru…

This study examines medical records from thousands of people with cancer who also had a blood clot (VTE). Researchers want to see which blood-thinning treatments are used, how well they work, and what the costs are. No new treatments are tested—just existing data is reviewed to l…

This study follows people with different cancers who have already received treatment in an earlier study. The main goal is to track serious side effects and other health issues over time. No new treatment is given; participants are simply monitored for safety.

This study provides standard cancer care to patients at the National Cancer Institute while collecting their medical information for research. It is open to adults and children aged 2 and older who need cancer treatment or consultation. No experimental therapies are offered; the …

This study tests a program called Potlako+ that combines community education, help for healthcare workers, and patient guides to speed up cancer detection and treatment. About 874 adults in Botswana with cancer symptoms or at risk will take part. Half the communities get the prog…

This study follows 500 children with growth hormone deficiency who are taking somapacitan as part of their normal care. Researchers will monitor side effects, medication errors, and whether any children develop new health problems like cancer or type 2 diabetes over 10 years. The…